V920 Vaccine
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Ebola Virus
Conditions
Ebola Virus
Trial Timeline
Dec 5, 2014 → Jun 23, 2016
NCT ID
NCT02314923About V920 Vaccine
V920 Vaccine is a phase 1 stage product being developed by Merck for Ebola Virus. The current trial status is completed. This product is registered under clinical trial identifier NCT02314923. Target conditions include Ebola Virus.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02314923 | Phase 1 | Completed |
Competing Products
20 competing products in Ebola Virus